.png "Amicus (NASDAQ: FOLD)")
Chardan Capital analyst Gbola Amusa reiterated a Hold rating on Amicus (NASDAQ: FOLD) today and set a price target of $15. The company’s shares closed yesterday at $11.75, close to its 52-week low of $11.57.
According to TipRanks.com, Amusa is a 5-star analyst with an average return of 19.9% and a 46.2% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Currently, the analyst consensus on Amicus is a Moderate Buy with an average price target of $23.
See today’s analyst top recommended stocks >>
Based on Amicus’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $61.83 million. In comparison, last year the company had a GAAP net loss of $112 million.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FOLD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease.
